Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
177.30 K
Value Traded
-
Short % Float
1.06%
Days to Cover
1.0
-2.92%Week
-20.88%1 Month
-32.23%3 Month
-32.23%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
563.65 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
62.77 M
Float Shares
38.52 M
Insiders
38.62%
Institutions
8.74%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ETRA Catalyst Timeline
Dated clinical, regulatory and corporate events for Electra Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How ETRA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ETRA program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLCDirector, 10% Owner | Buy | 333,333 5,126,891 held | $15.00 | 09/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ETRA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ETRA for Q2 2026. | ||||
ETRA Institutional Ownership Trends
ETRA Short Interest
Shares sold short, counted twice a month.
1.06%
Short % of Float
of tradable shares sold short
409.4K
Shares Sold Short
-41.7% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
516.1K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ETRA ranks across every disease it competes in
Competitive Position is a premium feature
See how ETRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialETRA News
-ETRA
Sep 18, 2026Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering
Electra Therapeutics has announced the pricing of its upsized initial public offering, raising approximately $350 million by offering 23,333,334 shares at $15.00 each. The shares are set to begin trading on Nasdaq under the ticker ETRA on September 18, 2026, with the offering expected to close on September 21, 2026. This funding will support the company's development of precision medicines for immune-mediated diseases and cancer.
Read more →-ETRA
Sep 10, 2026Electra Therapeutics Announces Initiation of a Phase 1 Trial of ELA822, a Novel SIRPγ-Specific Antibody Designed to Treat T Cell-Mediated Immune and Inflammatory Diseases
Electra Therapeutics has initiated a Phase 1 clinical trial for ELA822, a novel SIRPγ-specific monoclonal antibody aimed at treating T cell-mediated immune and inflammatory diseases. The trial will assess the safety, tolerability, and pharmacokinetics of ELA822 in healthy volunteers. Preclinical studies indicated that ELA822 effectively depletes activated T cells while sparing regulatory T cells, showing promise for chronic disease applications.
Read more →-ETRA
Sep 9, 2026Electra Therapeutics Appoints Chris Clark, CFA, to Chief Financial Officer
Electra Therapeutics has promoted Chris Clark to Chief Financial Officer. Clark, who joined in December 2025, has over 20 years of experience in biopharmaceutical investments. His role will be crucial as the company advances its lead candidate, ipsoprubart, through global registrational programs and expands its clinical pipeline.
Read more →-ETRA
May 5, 2026Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies
Electra Therapeutics has dosed the first patient in a Phase 1 study of ipsoprubart (ELA026) targeting T cell malignancies. This first-in-class therapy aims to selectively deplete pathological T cells and myeloid cells, building on previous positive results in lymphoma patients. The study will evaluate safety and efficacy in adults with relapsed or refractory conditions.
Read more →-ETRA
Jan 5, 2026Electra Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Electra Therapeutics will present at the 44th annual J.P. Morgan Healthcare Conference from January 12-15, 2026. CEO Kathy Dong will discuss the company's SIRP-targeted therapies, including ELA026, which is in pivotal studies for secondary hemophagocytic lymphohistiocytosis. The company is also advancing ELA822 for immunology and inflammation diseases.
Read more →-ETRA
Dec 2, 2025Electra Therapeutics Presents SURPASS Pivotal ELA026 Study Design and Highlights the Critical Unmet Need in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) at the ASH 2025 Annual Meeting
Electra Therapeutics will present the SURPASS Phase 2/3 study design for ELA026 at the ASH 2025 Annual Meeting. This investigational therapy targets secondary hemophagocytic lymphohistiocytosis (sHLH) and aims to address significant unmet needs in treatment. The study's findings underscore the life-threatening nature of sHLH and the limited effectiveness of current therapies.
Read more →-ETRA
Oct 22, 2025Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer
Electra Therapeutics announced a $183 million Series C financing to support its lead candidate ELA026 in a pivotal trial for secondary hemophagocytic lymphohistiocytosis. The funding will also facilitate the expansion of ELA026 into hematologic cancers and advance the second pipeline program, ELA822.
Read more →-ETRA
Oct 22, 2025Electra Therapeutics Announces First Patients Dosed in the SURPASS Phase 2/3 Pivotal Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Electra Therapeutics announced the dosing of the first patients in the SURPASS Phase 2/3 study for ELA026, targeting secondary hemophagocytic lymphohistiocytosis (sHLH). ELA026 aims to treat this life-threatening condition by depleting pathological immune cells. The study will assess safety and efficacy, with promising results from previous trials indicating high survival rates.
Read more →-ETRA
Oct 22, 2025Electra Therapeutics Receives FDA Breakthrough Therapy and EMA Priority Medicines Designations for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Electra Therapeutics announced that ELA026 has received FDA Breakthrough Therapy and EMA Priority Medicines designations for secondary hemophagocytic lymphohistiocytosis (sHLH). The drug demonstrated a 100% overall survival rate in a Phase 1b study for malignancy-associated HLH patients. Electra has initiated the SURPASS global pivotal trial to further evaluate ELA026's efficacy.
Read more →-ETRA
Aug 4, 2025Electra Therapeutics Announces ELA026 Granted EMA Orphan Drug Designation for the Treatment of Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Electra Therapeutics announced that ELA026 has been granted Orphan Drug Designation by the EMA for treating secondary hemophagocytic lymphohistiocytosis (sHLH). This designation highlights the urgent need for effective therapies for this rare, life-threatening condition. ELA026 is designed to selectively deplete harmful immune cells, potentially improving patient outcomes.
Read more →About Electra Therapeutics, Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next ETRA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime